Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.9252W HIGH $36.20
Volume
542.00
Value Traded
353.36 K
Short % Float
2.9%
Days to Cover
4.7
+1.58%Week
+9.57%1 Month
-18.38%3 Month
-67.07%6 Month
-99.92%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
44.99 M
EPS (TTM)
1.66
P/E Ratio
3.10
Ent. Value
34.93 M
Total Shares
8.60 M
Float Shares
8.14 M
Insiders
5.42%
Institutions
47.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
SNWV Catalyst Timeline
Dated clinical, regulatory and corporate events for SANUWAVE Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SANUWAVE Health, Inc.
789Total events
0Upcoming
106Tier-1 (high impact)
2012 to 2026Coverage
Event history 50
▲Quarterly UpdateCorporate
On pace for record quarterly unit volume of applicator shipments in Q2
●R&D DayPresentation
Sanuwave to participate in 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchUltraMISTPost-Market
UltraMIST rollout to Healogics iSupply members at initial locations
▲Other Regulator MilestoneUltraMISTEx-US Regulatory
CMS publishes final rule for 2026 Physician Fee Schedule for UltraMIST procedure
●Quarterly UpdateCorporate
Company to file Form 8-K with additional details on credit facility
▲Debt Royalty FinancingCorporate
Sanuwave refinances NH Expansion debt with new J.P. Morgan credit facility
▲Quarterly UpdateCorporate
Company forecasts Q4 2024 revenue of $9.7 to $10.5 million (40-50% increase from Q4 2023)
Past FDA Catalysts and PDUFA Decisions
How SNWV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
SANUWAVE Health, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SNWV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| dermaPACE | Diabetic Foot Ulcers | Phase 3 | 2016-03-24 | 35.47% vs. 24.39%; p=0.027 at 20 weeks; 37.79% vs. 26.22%; p=0.023 at 24 weeks; 22.67% vs. 18.29%; p=0.320 at 12 weeks; 1.92cm2 versus 0.16cm2; p=0.047 at 24 weeks; 18.0% versus 31.1%; p=0.005 at 12 weeks; 25.6% versus 34.2%; p=0.086 at 24 weeks; 2.3% vs. 3.0%; p=0.745Read More | SANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot UlcersRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Blizard JeffreyDirector | Grant/Award | 5,524 5,524 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNWV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.3 % (-86.4 %) | 3.06 M | 306.14 K | -68.8% ( -675.13 K) |
Ownership Trends
SNWV Short Interest
Shares sold short, counted twice a month.
2.9%
Short % of Float
of tradable shares sold short
236.2K
Shares Sold Short
-3.8% vs prior count
4.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
50.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNWV ranks across every disease it competes in
Competitive Position is a premium feature
See how SNWV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNWV News
SNWVSanuwave Announces Q2 FY2026 Financial Results
Sanuwave Health, Inc. reported Q2 2026 revenues of $9.7 million, a 3% decline from the previous year. The company experienced an operating loss of $(0.3) million, contrasting with a profit in Q2 2025. Despite challenges, Ultramist applicator sales showed a 13% increase, indicating ongoing demand. Sanuwave has withdrawn its fiscal year 2026 guidance amid uncertainties in the reimbursement landscape.
Read more →SNWV▲ +6.2%on this news· ran to -43% by day 3
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
Sanuwave Health reported preliminary revenues for Q2 2026 between $9.6 and $9.8 million, surpassing its revised guidance. Despite a 3-5% decrease from the previous year, record sales of consumable applicators suggest growing confidence in their Ultramist technology. The company is also addressing challenges in capital sales through a trade-in program for used systems.
Read more →SNWV▼ -42%on this news
Sanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave Health has updated its revenue guidance for Q2 2026 to between $8.5 and $9.5 million, reflecting a decline from earlier projections. The company faces market disruptions affecting sales of its Ultramist system due to reimbursement clawbacks. Despite these challenges, Sanuwave reports strong applicator sales and remains optimistic about its product pipeline.
Read more →SNWV▲ +18.1%on this news
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Sanuwave Health reported Q1 2026 revenues of $9.6 million, marking a 3.1% increase from the previous year, and the highest Q1 revenues in its history. Despite a GAAP operating loss of $1.1 million, the company anticipates a 10-15% revenue growth for Q2 2026. CEO Morgan Frank noted a recovery in sales, particularly in applicator sales, and expressed optimism for continued growth throughout 2026.
Read more →SNWVSanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
Sanuwave Health, Inc. has announced it will hold a conference call on May 13, 2026, at 8:30 AM (ET) to discuss its Q1 2026 financial results. The call will provide investors with insights into the company's financial performance, alongside the details available on their website. Sanuwave focuses on developing and commercializing advanced non-invasive medical systems aimed at wound care and tissue regeneration. However, investors are cautioned regarding forward-looking statements as they involve risks that could affect actual results.
Read more →SNWVSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Sanuwave Health has reported preliminary revenues for Q1 2026 ranging from $9.6 million to $9.7 million, representing a 3-4% increase year-over-year. The results align with previous financial guidance, though the revenue came in at the lower end of expectations due to delayed deals. CEO Morgan Frank expressed optimism about the company’s Ultramist product and noted increased interest from practitioners at a recent conference. However, the market is experiencing challenges related to changes in reimbursement policies, prompting a cautious approach from some healthcare providers.
Read more →SNWVSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6-$9.7 Million, Up 3-4% Year-over-Year
Sanuwave Health has reported preliminary revenues for Q1 2026 in the range of $9.6 to $9.7 million, marking a 3-4% increase from the same period last year. This figure aligns with previously set guidance, although the CEO noted that some anticipated deals did not close in the quarter. Factors such as changes in reimbursement policies for wound care products have caused market hesitancy among practitioners. Despite these challenges, interest in Sanuwave's offerings remains high, as evidenced by strong engagement at recent industry conferences.
Read more →SNWVSanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Sanuwave Health, Inc. reported record revenues of $13.4 million for Q4 2025, marking a 29.7% increase from the previous year. The full year revenue reached $44.1 million, up 35.0% from 2024. Despite challenges in the wound care sector, the company anticipates continued growth with guidance for Q1 2026 revenues between $9.6 and $10.3 million. The CEO highlighted the potential for their UltraMIST product amidst industry changes.
Read more →SNWVSanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
Sanuwave Health, Inc. will hold a conference call on March 27, 2026, to discuss its financial results for Q4 and the full year of 2025. This announcement highlights the company's ongoing focus on developing and commercializing advanced wound care products. Participants can access the call via telephone or through a dedicated online link. A replay of the call will be available afterward for those who cannot attend the live event.
Read more →SNWVSanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health announced preliminary revenues of $13.3 to $13.4 million for Q4 2025, marking a 29%-30% increase from Q4 2024. The full-year revenue for 2025 reached $44.3-$44.4 million, a 36% increase compared to the previous year. The company attributed its success to strategic adaptations in the evolving wound care market, positioning itself for future opportunities.
Read more →SNWVSanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Sanuwave Health, Inc. will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to January 15, 2026. The company aims to connect with investors during the event. Sanuwave focuses on developing FDA-approved wound care products and regenerative medicine technologies.
Read more →SNWV▼ -8.6%on this newsshared move
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Sanuwave Health has announced the addition of its UltraMIST product line to Healogics' iSupply Group Purchasing Organization. This collaboration allows iSupply members, including various healthcare facilities, to access UltraMIST, which is expected to be rolled out by the end of 2025. The partnership aims to provide innovative wound care solutions and enhance patient care.
Read more →SNWV▲ +17.7%on this news· ran to +30% by day 1
Sanuwave Announces Q3 FY2025 Financial Results
Sanuwave Health, Inc. reported Q3 2025 revenues of $11.5 million, a 22% increase from the previous year, marking the highest quarterly revenue in its history. The gross margin improved to 77.9%, although GAAP operating income decreased to $1.5 million due to stock-based compensation costs. The company anticipates Q4 2025 revenues between $13-$14 million despite industry challenges related to reimbursement changes.
Read more →SNWVSanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Sanuwave Health, Inc. will conduct a conference call on November 7, 2025, at 8:30 AM (ET) to discuss its Q3 2025 financial results. The call will be accessible via telephone and a link for instant access is provided. Sanuwave specializes in FDA-approved wound care products and aims to improve healing processes through its innovative technologies.
Read more →SNWV▼ -5.3%on this newsshared move
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
Sanuwave Health, Inc. announced that the final rule for the 2026 Physician Fee Schedule by CMS maintains reimbursement rates for the UltraMIST procedure (CPT code 97610) largely unchanged from 2025. The company expects slight increases in reimbursement for many providers, aligning with their prior expectations. CEO Morgan Frank emphasized the stability of these rates amidst changes in other wound care reimbursements.
Read more →SNWV▼ -21.6%on this news
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
Sanuwave Health announced preliminary revenues of $11.4 to $11.6 million for Q3 2025, marking the highest quarterly revenue in its history. This represents a 22-24% increase compared to Q3 2024, although it fell short of earlier guidance. The CEO noted challenges in the wound care market due to reimbursement uncertainties, leading to delayed purchasing decisions. Despite these challenges, the company recorded a significant number of system sales and plans to adjust its annual revenue guidance.
Read more →SNWVSanuwave Announces Strategic Debt Refinancing with New Credit Facility
Sanuwave Health, Inc. has announced a strategic refinancing of its debt through a new credit facility from J.P. Morgan. The $23 million term loan and $5 million revolving credit facility will help repay the existing NH Expansion debt. This move is expected to improve the company's financial position and cash flow management.
Read more →SNWV▲ +15.9%on this news
Sanuwave Announces Q2 FY2025 Financial Results
Sanuwave Health, Inc. reported its Q2 FY2025 financial results, showcasing a 42% increase in revenues to $10.2 million, marking the highest quarterly revenues in the company's history. The gross margin improved to 78.3%, up from 73.2% in the same quarter last year. Despite the positive revenue trends, the company's GAAP operating income and net income fell compared to Q2 2024 due to increased expenses and a lack of significant one-time gains. Sanuwave forecasts revenues of $12-$12.7 million for Q3 2025, reiterating its full-year revenue guidance of $48-$50 million.
Read more →SNWVSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results
Sanuwave Health, Inc. has announced a conference call scheduled for August 8, 2025, at 8:30 AM (ET) to present its financial results for Q2 2025. The firm specializes in FDA-approved wound care products and regenerative medicine. Interested parties can join the call via telephone or online, with materials available on their investor website. A replay of the call will be accessible until August 29, 2025.
Read more →SNWVSanuwave Health to Present at Canaccord Genuity Growth Conference
Sanuwave Health, Inc. will present at the 45th Annual Canaccord Genuity Growth Conference on August 13, 2025. CEO Morgan Frank will lead the presentation and is available for one-on-one investor meetings. The company specializes in FDA-approved wound care products and regenerative medicine technologies.
Read more →About SANUWAVE Health, Inc.
Headquarters9600 W. 76TH STREET, EDEN PRAIRIE, MN
BIOPHARMAWATCH ELITE PLUS
Trade the next SNWV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime